LENZ Therapeutics, Inc.

LENZ Therapeutics announced a strategic reorganization to prioritize consumer marketing and reduce operating expenses, including a ~75% workforce reduction and an estimated $5 million in restructuring charges. The company reported Q3 2026 product sales of $2.6 million, a 50% increase from the prior quarter. Additionally, CEO Eef Schimmelpennink will transition to an interim advisory role on December 1, 2026, with CFO Dan Chevallard succeeding him as Interim CEO. The reorganization is expected to reduce 2027 annualized operating expenses by over 50%.

LENZ Therapeutics reported its first product sales of VIZZ® following FDA approval in July 2025, with Q2 2026 product sales reaching $1.736 million and total revenue of $5.486 million. Despite this new revenue stream, the company posted a net loss of $31.918 million for the quarter, increasing its accumulated deficit to $300.5 million. LENZ maintains a strong liquidity position with $220.0 million in cash, cash equivalents, and marketable securities, which it expects to be sufficient for at least the next 12 months.

LENZ Therapeutics reported Q2 2026 total revenue of $5.5 million, including $1.7 million from VIZZ product sales, which increased 9% over Q1 2026. The company posted a net loss of $31.9 million for the quarter. Key commercial highlights include strong patient persistence for VIZZ, with over 60% of ePharmacy patients purchasing multiple monthly packs, and the launch of a telehealth channel and national TV campaign in July 2026. LENZ also advanced its global strategy with new international partnerships and regulatory submissions for VIZZ in the UK, Canada, Australia, New Zealand, and Greater China.

LENZ Therapeutics, Inc. announced it will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT. The webcast will cover the company's second quarter 2026 financial results and recent corporate highlights. Investors can access the event via telephone or a live webcast on the company's website, with a replay available for 30 days.

LENZ Therapeutics, Inc. announced the launch of a new telehealth platform for VIZZ (aceclidine ophthalmic solution) 1.44%, its eye drop for presbyopia. This platform provides patients with convenient online evaluations by licensed eye care providers, e-pharmacy prescription fulfillment, and home delivery. The company is promoting this new access channel with a national television advertising campaign featuring brand spokesperson Sarah Jessica Parker, aiming to significantly expand consumer awareness, access, and adoption of VIZZ among the 128 million Americans affected by presbyopia.

Zach Scheiner resigned from LENZ Therapeutics, Inc.'s Board of Directors and all committees, effective June 30, 2026. The company stated his resignation was not due to any dispute or disagreement. Following his departure, the Board reduced its size to six members and appointed Jeff George to the Audit Committee.

LENZ Therapeutics, Inc. announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for VIZZ, its FDA-approved presbyopia treatment, in Australia and New Zealand. Under the terms, LENZ will receive an upfront payment and a significant profit share from gross margin, while Arrotex gains exclusive commercialization rights. This partnership marks LENZ's fifth ex-US commercialization deal for VIZZ, expanding its global reach for the innovative eye drop.

LENZ Therapeutics announced that Everest Medicines acquired the rights to develop, manufacture, and commercialize VIZZ (LNZ100) in Greater China from Corxel Pharmaceuticals. This agreement transfers the existing license rights and obligations to Everest. LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones, along with tiered mid single-digit to low double-digit royalties on net sales in the region. The New Drug Application for LNZ100 in China was submitted in September 2025, with approval anticipated in Q1 2027.

LENZ Therapeutics, Inc. announced that its management will participate in three upcoming investor conferences in June 2026. The company plans to hold 1x1 investor meetings at the William Blair 46th Annual Growth Stock Conference, the 2026 Jefferies Global Healthcare Conference, and the Goldman Sachs 47th Annual Global Healthcare Conference. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmologic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia.

LENZ Therapeutics reported Q1 2026 total revenue of $1.9 million, driven by $1.7 million in VIZZ product sales, a 19% increase over Q4 2025. The company recorded a net loss of $41.5 million due to significant planned launch investments in selling, general, and administrative expenses. LENZ also highlighted strong commercial progress with approximately 46,000 paid VIZZ prescriptions since launch, an expanded sales force, and international regulatory submissions and partnerships, maintaining a cash position of $258.4 million.